News Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer Staff September 11, 2023 Iframe sync Post Navigation Previous EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023Next Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference More Stories News Lam Research Corporation Declares Quarterly Dividend Staff May 21, 2025 DNA News Pharmaceutical Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer Staff May 21, 2025 Cancer Financial Healthcare News GRAIL to Present at Jefferies Global Healthcare Conference 2025 Staff May 21, 2025
